Loading clinical trials...

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer

NCT00836927•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for whom a clinical benefit has been established in a prior parent trial (MK-8669-013, NCT00060645; MK-8669-016, NCT00112372; and MK-8669-028, NCT00704054) with deforolimus and/or in those who remain in long-term follow-up.

Eligibility

Age

1 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must have participated on a deforolimus (ridaforolimus) parent trial
•Must have derived a clinical benefit from the parent trial
•Is not on any other anti-cancer treatment(s) unless the therapy was allowed on the parent protocol
•Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 if the participant is scheduled to receive treatment with deforolimus; no requirement if the participant is included for follow-up purposes only
•Participant of childbearing potential must have a negative pregnancy test within 7 days prior to screening and must use approved contraceptive from screening until 30 days after the last dose of study drug
•Signed informed consent

Exclusion Criteria

•Has not participated on a parent trial
•Women who are to receive study drug who are pregnant or lactating
•Any condition in the Investigator's judgment that renders the participant unable to fully understand and provide informed consent and/or comply with the protocol

Key Dates

Start Date

February 1, 2009

Primary Completion Date

April 3, 2017

Completion Date

February 4, 2018

Last Updated

February 18, 2019

Enrollment

ACTUAL participants

Conditions

Advanced Cancers

Interventions

Ridaforolimus Tablet

DRUG

Ridaforolimus Intravenous (IV) Infusion

DRUG

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT07260708

Advanced Cancers

View study

RECRUITINGPHASE1

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

NCT06413953

Advanced Cancers

View study

RECRUITINGPHASE1/PHASE2

Plasmodium Immunotherapy for Advanced Cancers

NCT03375983

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Inclusion Criteria

Exclusion Criteria

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Plasmodium Immunotherapy for Advanced Cancers

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer